Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer
•Currently, only FFPE samples are acceptable for the IHC assessment of PD-L1 in NSCLC.•Cytological smears are the only available material for a subset of patients.•IHC for PD-L1 in cytological smears of NSCLC is feasible using the >50% cut-off.•PD-L1 IHC on cytological smears expands the pool of...
Uložené v:
| Vydané v: | Lung cancer (Amsterdam, Netherlands) Ročník 126; s. 9 - 14 |
|---|---|
| Hlavní autori: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Ireland
Elsevier B.V
01.12.2018
|
| Predmet: | |
| ISSN: | 0169-5002, 1872-8332, 1872-8332 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | •Currently, only FFPE samples are acceptable for the IHC assessment of PD-L1 in NSCLC.•Cytological smears are the only available material for a subset of patients.•IHC for PD-L1 in cytological smears of NSCLC is feasible using the >50% cut-off.•PD-L1 IHC on cytological smears expands the pool of NSCLC candidate to immunotherapy.
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients.
Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case.
Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy. |
|---|---|
| AbstractList | •Currently, only FFPE samples are acceptable for the IHC assessment of PD-L1 in NSCLC.•Cytological smears are the only available material for a subset of patients.•IHC for PD-L1 in cytological smears of NSCLC is feasible using the >50% cut-off.•PD-L1 IHC on cytological smears expands the pool of NSCLC candidate to immunotherapy.
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients.
Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case.
Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy. Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients. Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case. Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy. Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients. Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case. Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy.Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 paired histological samples and cytological smears of NSCLC patients. Results The accuracy of the three antibodies for the detection of PD-L1 in histological samples was higher for the antibody SP263 (AUC/ROC = 1) compared to the clones 28-8 (AUC/ROC =,991) and 22-C3 (AUC/ROC =,942). The overall concordance between histological samples and cytological smears using the SP263 clone was moderate (kappa = 0,364). However when the cyto-histological concordance was calculated using just the <50% vs ≥50% cut-off the agreement (kappa = 0.626) was good. The accuracy of the antibody SP263 in cytological smears was good (AUC/ROC =,921). A fluorescent in situ hybridization analysis on 10 histological cases positive for PD-L1 at immunohistochemistry showed amplification of the CD274 gene only in one case. Conclusions Immunocytochemical staining for PD-L1 in diagnostic cytological smears of NSCLC is feasible and applicable at least using the >50% cancer cell cut-off. The three antibodies SP263, 22-C3 and 28-8 are all suitable for the diagnostic detection of PD-L1 on tissue sections with a superiority of the SP263 clone. The implementation of PD-L1 immunocytochemistry on cytological smears will likely expand the pool of NSCLC patients candidate to first-line immunotherapy. |
| Author | Gelsomino, Francesco Trisolini, Rocco Capizzi, Elisa Casolari, Laura Giunchi, Francesca Ceccarelli, Claudio Ardizzoni, Andrea Ricci, Costantino Gómez, Begoña Urrios Álvarez Zagnoni, Stefano Fiorentino, Michelangelo |
| Author_xml | – sequence: 1 givenname: Elisa surname: Capizzi fullname: Capizzi, Elisa organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 2 givenname: Costantino surname: Ricci fullname: Ricci, Costantino organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 3 givenname: Francesca surname: Giunchi fullname: Giunchi, Francesca organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 4 givenname: Stefano surname: Zagnoni fullname: Zagnoni, Stefano organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 5 givenname: Claudio surname: Ceccarelli fullname: Ceccarelli, Claudio organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 6 givenname: Begoña Urrios Álvarez surname: Gómez fullname: Gómez, Begoña Urrios Álvarez organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 7 givenname: Laura surname: Casolari fullname: Casolari, Laura organization: Department of Thoracic Endoscopy, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 8 givenname: Francesco surname: Gelsomino fullname: Gelsomino, Francesco organization: Department of Thoracic Endoscopy, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 9 givenname: Rocco surname: Trisolini fullname: Trisolini, Rocco organization: Department of Medical Oncology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 10 givenname: Michelangelo orcidid: 0000-0002-1749-150X surname: Fiorentino fullname: Fiorentino, Michelangelo email: michelangelo.fiorentino@unibo.it organization: Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy – sequence: 11 givenname: Andrea surname: Ardizzoni fullname: Ardizzoni, Andrea organization: Department of Thoracic Endoscopy, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30527198$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1uEzEUhS1URNPCI4C8LIsJ9kwm9gghhMqvFAkWwNa6se8kDh472J6KvAZPjKcJLLopkn-k6-9c-dxzQc588EjIU87mnPHli93cjX6jwc9rxmWpzRkXD8iMS1FXsmnqMzIrXFe1jNXn5CKlHSsEZ90jct6wtha8kzPy-zs4ayDb4Gnoad4itcMw-rC1KQe9xcFqcBR_7SOmdKL2MWwiDAMaahDyljq7AW8op1df3lYr_pwWTh9ycGFzK08DQkzUegrmBrwuwmKnlME5qrEckxmqp6f4mDzswSV8crovybf3775ef6xWnz98un6zqnTb1LlCI4qbFjvDlmVztm6MFGK9bHoJKOVCQ98IvTCsLANCLHsppZE1FxpQ6OaSXB37Fjs_R0xZDTZNnwGPYUyq5m3LFx1f1AV9dkLHdXGt9tEOEA_q7xwL0B4BHUNKEft_CGdqykvt1CkvNeU1lUsaRffyjk7bfJtGjmDdverXRzWWMd1YjCppi9N4bUSdlQn23g6v7nTQzvopsx94-A_9H6BDyvA |
| CitedBy_id | crossref_primary_10_1111_cyt_12743 crossref_primary_10_1016_j_prp_2022_153893 crossref_primary_10_1016_j_chest_2023_09_013 crossref_primary_10_5858_arpa_2023_0483_CP crossref_primary_10_1111_apm_13223 crossref_primary_10_1111_cyt_12982 crossref_primary_10_1038_s41571_021_00520_1 crossref_primary_10_1177_1758835920954802 crossref_primary_10_1002_dc_24646 crossref_primary_10_1007_s00428_019_02632_7 crossref_primary_10_1016_j_lungcan_2020_01_010 crossref_primary_10_2217_imt_2019_0138 crossref_primary_10_1111_cyt_12795 crossref_primary_10_1038_s41379_019_0339_0 crossref_primary_10_1111_cas_14128 crossref_primary_10_3389_pore_2024_1611733 crossref_primary_10_1002_cncy_22216 crossref_primary_10_1159_000517078 crossref_primary_10_1002_dc_25043 crossref_primary_10_1007_s00432_021_03615_5 crossref_primary_10_1186_s12885_020_06851_z crossref_primary_10_1002_dc_24654 crossref_primary_10_1136_jclinpath_2019_205732 crossref_primary_10_1002_dc_24955 crossref_primary_10_1016_j_urolonc_2020_09_012 crossref_primary_10_1016_j_jasc_2022_04_004 |
| Cites_doi | 10.5858/arpa.2017-0208-RA 10.5858/arpa.2015-0542-OA 10.1186/s13000-016-0545-8 10.21037/jtd.2018.04.50 10.1056/NEJMoa1606774 10.1016/j.jtho.2016.11.2228 10.1002/cncy.21987 10.1097/JTO.0b013e3182a471a9 10.1111/crj.12736 10.1016/j.jtho.2018.05.013 10.1159/000368857 10.1093/annonc/mdy126 10.1016/j.jtho.2018.04.017 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.lungcan.2018.10.017 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-8332 |
| EndPage | 14 |
| ExternalDocumentID | 30527198 10_1016_j_lungcan_2018_10_017 S0169500218306019 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 4.4 457 4CK 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SEL SES SEW SPCBC SSH SSU SSZ T5K UDS WUQ X7M Z5R ZGI ~G- ~HD AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW DOVZS LCYCR RIG 9DU AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c532t-ed77105e9d069d010b3d877b63f8ae884caf37c4d04d0da776f888d8217cae7c3 |
| ISICitedReferencesCount | 29 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000455069300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0169-5002 1872-8332 |
| IngestDate | Mon Sep 29 04:19:19 EDT 2025 Thu Apr 03 06:57:35 EDT 2025 Sat Nov 29 03:54:04 EST 2025 Tue Nov 18 22:17:17 EST 2025 Fri Feb 23 02:26:21 EST 2024 Tue Oct 14 19:35:58 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Immunohistochemistry PD-L1 Lung cancer Smears Cytology |
| Language | English |
| License | Copyright © 2018 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c532t-ed77105e9d069d010b3d877b63f8ae884caf37c4d04d0da776f888d8217cae7c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-1749-150X |
| OpenAccessLink | http://hdl.handle.net/11585/655631 |
| PMID | 30527198 |
| PQID | 2155149142 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2155149142 pubmed_primary_30527198 crossref_primary_10_1016_j_lungcan_2018_10_017 crossref_citationtrail_10_1016_j_lungcan_2018_10_017 elsevier_sciencedirect_doi_10_1016_j_lungcan_2018_10_017 elsevier_clinicalkey_doi_10_1016_j_lungcan_2018_10_017 |
| PublicationCentury | 2000 |
| PublicationDate | December 2018 2018-12-00 2018-Dec 20181201 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: December 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland |
| PublicationTitle | Lung cancer (Amsterdam, Netherlands) |
| PublicationTitleAlternate | Lung Cancer |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Dolled-Filhart, Roach, Toland (bib0015) 2016 Trisolini, Natali, Ferrari, Livi, Paioli, Romagnoli, Cancellieri (bib0040) 2018; 12 Hirsch, McElhinny, Stanforth, Ranger-Moore (bib0055) 2017; 12 Lozano, Echeveste, Abengozar (bib0050) 2018; 142 Munari, Rossi, Zamboni, Lunardi, Marconi, Sommaggio, Netto, Hoque, Brunelli, Martignoni, Haffner, Moretta, Pegoraro, Cavazza, Samogin, Furlan, Mariotti, Vacca, Moretta, Bogina (bib0065) 2018; 12 Noll, Wang, Gong (bib0060) 2018; 126 Folch, Yamaguchi, VanderLaan (bib0035) 2013; 8 Kinoshita, Ujiie, Schwock (bib0030) 2018; 10 Wang, Agulnik, Kasymjanova (bib0045) 2018; 1 Rebelatto, Midha, Mistry (bib0020) 2016; 8 Munari, Zamboni, Lunardi, Marchionni, Marconi, Sommaggio, Brunelli, Martignoni, Netto, Hoque, Moretta, Mingari, Pegoraro, Inno, Paiano, Terzi, Cavazza, Rossi, Mariotti, Vacca, Moretta, Bogina (bib0070) 2018; 13 Reck, Rodríguez-Abreu, Robinson (bib0005) 2016; 375 Van der Heijden, Casal, Trisolini (bib0025) 2014; 88 Giunchi, Degiovanni, Daddi, Trisolini, Dell’Amore, Agostinelli, Ardizzoni, Fiorentino (bib0075) 2016 Tsao, Kerr, Kockx (bib0010) 2018 Kinoshita (10.1016/j.lungcan.2018.10.017_bib0030) 2018; 10 Dolled-Filhart (10.1016/j.lungcan.2018.10.017_bib0015) 2016 Giunchi (10.1016/j.lungcan.2018.10.017_bib0075) 2016 Rebelatto (10.1016/j.lungcan.2018.10.017_bib0020) 2016; 8 Trisolini (10.1016/j.lungcan.2018.10.017_bib0040) 2018; 12 Wang (10.1016/j.lungcan.2018.10.017_bib0045) 2018; 1 Van der Heijden (10.1016/j.lungcan.2018.10.017_bib0025) 2014; 88 Folch (10.1016/j.lungcan.2018.10.017_bib0035) 2013; 8 Munari (10.1016/j.lungcan.2018.10.017_bib0065) 2018; 12 Lozano (10.1016/j.lungcan.2018.10.017_bib0050) 2018; 142 Noll (10.1016/j.lungcan.2018.10.017_bib0060) 2018; 126 Munari (10.1016/j.lungcan.2018.10.017_bib0070) 2018; 13 Tsao (10.1016/j.lungcan.2018.10.017_bib0010) 2018 Hirsch (10.1016/j.lungcan.2018.10.017_bib0055) 2017; 12 Reck (10.1016/j.lungcan.2018.10.017_bib0005) 2016; 375 |
| References_xml | – volume: 8 start-page: 1438 year: 2013 end-page: 1444 ident: bib0035 article-title: Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer publication-title: J. Thorac. Oncol. – volume: 88 start-page: 500 year: 2014 end-page: 517 ident: bib0025 article-title: World association for bronchology and interventional pulmonology, task force on specimen guidelines. Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer publication-title: Respiration – year: 2018 ident: bib0010 article-title: PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project publication-title: J. Thorac. Oncol. – volume: 142 start-page: 291 year: 2018 end-page: 298 ident: bib0050 article-title: Cytology smears in the era of molecular biomarkers in non-small cell lung Cancer: doing more with less publication-title: Arch. Pathol. Lab. Med. – volume: 1 start-page: 1417 year: 2018 end-page: 1422 ident: bib0045 article-title: Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer publication-title: Ann. Oncol. – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: bib0005 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. – year: 2016 ident: bib0015 article-title: Development of a companion diagnostic for pembrolizumab in non-small cell lung Cancer Using immunohistochemistry for programmed death Ligand-1 publication-title: Arch. Pathol. Lab. Med. – volume: 126 start-page: 342 year: 2018 end-page: 352 ident: bib0060 article-title: Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations publication-title: Cancer Cytopathol. – volume: 12 year: 2018 ident: bib0065 article-title: PD-L1 assays 22-C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists publication-title: Am. J. Surg. Pathol. – volume: 8 start-page: 95 year: 2016 ident: bib0020 article-title: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma publication-title: Diagn. Pathol. – volume: 10 start-page: 2388 year: 2018 end-page: 2396 ident: bib0030 article-title: Clinical evaluation of the utility of a flexible 19-gauge EBUS-TBNA needle publication-title: J. Thorac. Dis. – volume: 13 start-page: 1113 year: 2018 end-page: 1120 ident: bib0070 article-title: PD-L1 expression heterogeneity in non-small cell lung Cancer: defining criteria for harmonization between biopsy specimens and whole sections publication-title: J. Thorac. Oncol. – volume: 12 start-page: 1725 year: 2018 end-page: 1731 ident: bib0040 article-title: Endobronchial ultrasound-guided transbronchial needle aspiration with the flexible 19-gauge needle publication-title: Clin. Respir. J. – start-page: 31 year: 2016 ident: bib0075 article-title: Fading with time of PD-L1 immunoreactivity in non-small cells lung cancer tissues: a methodological study publication-title: Appl. Immunohistochem. Mol. Morphol. – volume: 12 start-page: 208 year: 2017 end-page: 222 ident: bib0055 article-title: PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J. Thorac. Oncol. – volume: 142 start-page: 291 issue: March (3) year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0050 article-title: Cytology smears in the era of molecular biomarkers in non-small cell lung Cancer: doing more with less publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2017-0208-RA – volume: 12 issue: June year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0065 article-title: PD-L1 assays 22-C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists publication-title: Am. J. Surg. Pathol. – year: 2016 ident: 10.1016/j.lungcan.2018.10.017_bib0015 article-title: Development of a companion diagnostic for pembrolizumab in non-small cell lung Cancer Using immunohistochemistry for programmed death Ligand-1 publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2015-0542-OA – volume: 8 start-page: 95 issue: October (1) year: 2016 ident: 10.1016/j.lungcan.2018.10.017_bib0020 article-title: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma publication-title: Diagn. Pathol. doi: 10.1186/s13000-016-0545-8 – volume: 10 start-page: 2388 issue: 4 year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0030 article-title: Clinical evaluation of the utility of a flexible 19-gauge EBUS-TBNA needle publication-title: J. Thorac. Dis. doi: 10.21037/jtd.2018.04.50 – volume: 375 start-page: 1823 issue: 19 year: 2016 ident: 10.1016/j.lungcan.2018.10.017_bib0005 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606774 – volume: 12 start-page: 208 issue: 2 year: 2017 ident: 10.1016/j.lungcan.2018.10.017_bib0055 article-title: PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.2228 – volume: 126 start-page: 342 issue: May (5) year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0060 article-title: Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations publication-title: Cancer Cytopathol. doi: 10.1002/cncy.21987 – start-page: 31 issue: October year: 2016 ident: 10.1016/j.lungcan.2018.10.017_bib0075 article-title: Fading with time of PD-L1 immunoreactivity in non-small cells lung cancer tissues: a methodological study publication-title: Appl. Immunohistochem. Mol. Morphol. – volume: 8 start-page: 1438 issue: 11 year: 2013 ident: 10.1016/j.lungcan.2018.10.017_bib0035 article-title: Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182a471a9 – volume: 12 start-page: 1725 issue: 4 year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0040 article-title: Endobronchial ultrasound-guided transbronchial needle aspiration with the flexible 19-gauge needle publication-title: Clin. Respir. J. doi: 10.1111/crj.12736 – year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0010 article-title: PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.05.013 – volume: 88 start-page: 500 issue: 6 year: 2014 ident: 10.1016/j.lungcan.2018.10.017_bib0025 publication-title: Respiration doi: 10.1159/000368857 – volume: 1 start-page: 1417 issue: June(6) year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0045 article-title: Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy126 – volume: 13 start-page: 1113 issue: August (8) year: 2018 ident: 10.1016/j.lungcan.2018.10.017_bib0070 article-title: PD-L1 expression heterogeneity in non-small cell lung Cancer: defining criteria for harmonization between biopsy specimens and whole sections publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.04.017 |
| SSID | ssj0017109 |
| Score | 2.3989127 |
| Snippet | •Currently, only FFPE samples are acceptable for the IHC assessment of PD-L1 in NSCLC.•Cytological smears are the only available material for a subset of... Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 9 |
| SubjectTerms | Cytology Immunohistochemistry Lung cancer PD-L1 Smears |
| Title | Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0169500218306019 https://dx.doi.org/10.1016/j.lungcan.2018.10.017 https://www.ncbi.nlm.nih.gov/pubmed/30527198 https://www.proquest.com/docview/2155149142 |
| Volume | 126 |
| WOSCitedRecordID | wos000455069300002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-8332 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017109 issn: 0169-5002 databaseCode: AIEXJ dateStart: 19950401 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6Dk17Qdwpl8lIPICqlNwaO49VGQI0pgkNVPESJbaDMrVp1bRT2c_gP_G_OMdxLqBWGw9IbRQ5Po7i88U-dr5zDiEvY1gjizSOLSlgieJ7SWIltnQs5UvGpQowhphONsFOT_lkEp51Or8qX5jLKctzvtmEi_-qaigDZaPr7D-ou24UCuAclA5HUDscb6T4r2BZy9oQRLsyQx-QuY4sLKr4AGpjGLC6lmFpwczYl2gT9qfZd9xRd9AAPXtrnTi4ewB1xY9VPVoWM-g6TadtiARQpZjh1278INCfrtGjFy8t20bwSVOM7Y9mGKxBGmQ2DsitTYpxvMiurjLDQyvqqeRzJoQuHc_Ryl1l-bwmFGUwY-uMxWXyEFU0pKRvSC_UuayQ5ZbGRspsfji8RSRR5YDNGYzonvfniO62x-Rw60xRblpcDLAn4ImR5McHyPMrXUlbQFnMNFJgYHSZU6bM_itEd3Vpj-y7bBjyLtkffTiefKw_ZyHhtXEfe7P1rofkoGpnl420aw2kbaHzO-S2WcTQUQm-u6Sj8nvk4JOhadwnPxsM0nlKQaN0CwZpg0Gs1WCQagzSEoPUoa80Al9TqNfCHy3xR7OcVvijoFWq8UcRfxSfn5ZAe0C-vDs-H7-3TPIPSww9d2UpyaDXhiqUdgB_x048yRlLAi_lseLcF3HqMeFLG34yZixIOeeSwxJbxIoJ7yHpwk3VY0KdRHjK9lIQsf3E82OwDmxHxcEwAWNMsB7xq-6OhImMjwlaplFFgbyIjMIiVBgWg8J6ZFCLLcrQMNcJBJUuo8rvGWbqCCB5nSCvBY1hXBq8NxF9UYEmgokDOz_O1XxdRK5eLIWO7_bIoxJN9WNUQHyy88pTcti8j89Id7Vcq-fklrhcZcXyiOyxCT8yb8Fvo_HueA |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+the+immunohistochemical+expression+of+programmed+death+ligand+1+%28PD-L1%29+on+cytological+smears+in+advanced+non+small+cell+lung+cancer&rft.jtitle=Lung+cancer+%28Amsterdam%2C+Netherlands%29&rft.au=Capizzi%2C+Elisa&rft.au=Ricci%2C+Costantino&rft.au=Giunchi%2C+Francesca&rft.au=Zagnoni%2C+Stefano&rft.date=2018-12-01&rft.eissn=1872-8332&rft.volume=126&rft.spage=9&rft_id=info:doi/10.1016%2Fj.lungcan.2018.10.017&rft_id=info%3Apmid%2F30527198&rft.externalDocID=30527198 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0169-5002&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0169-5002&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0169-5002&client=summon |